DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2006-01-20

Last Posted Date: 2016-09-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 210

Registration Number: NCT00279760

Locations: 🇬🇧
Local Institution, Leeds, United Kingdom
🇧🇪
Local Instiution, Bruxelles, Belgium

Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept + Vaccines
Drug: Tetanus + pnemococcal vaccines alone

First Posted Date: 2006-01-20

Last Posted Date: 2011-04-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 80

Registration Number: NCT00279734

Locations: 🇺🇸
Qutintiles Phase I Services, Lenexa, Kansas, United States
🇺🇸
PPD Development, Austin, Texas, United States
🇺🇸
Parexel International Corp, Baltimore, Maryland, United States

A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris

Phase 1

Completed

Conditions: Psoriasis Vulgaris

First Posted Date: 2006-01-16

Last Posted Date: 2011-04-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT00277225

Locations: 🇺🇸
California Clinical Trials Medical Group, Beverly Hills, California, United States

Comparability DE vs CD-CHO1

Phase 1

Completed

Conditions: Healthy Subjects

First Posted Date: 2006-01-16

Last Posted Date: 2011-04-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 30

Registration Number: NCT00277199

Locations: 🇬🇧
Inveresk Clinical Research, Edinburgh, United Kingdom

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: ATV
Drug: Tenofovi-Emtricitabine (TDF/FTC) tablet
Drug: RTV
Drug: LPV

First Posted Date: 2006-01-09

Last Posted Date: 2011-05-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1057

Registration Number: NCT00272779

Locations: 🇬🇧
Local Institution, Manchester, Greater Manchester, United Kingdom

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Phase 1

Completed

Conditions: Unresectable Stage III or IV Malignant Melanoma

Interventions: Drug: Ipilimumab

First Posted Date: 2005-12-05

Last Posted Date: 2016-09-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 80

Registration Number: NCT00261365

Locations: 🇺🇸
Comprehensive Cancer Center, Palm Springs, California, United States
🇺🇸
The Angeles Clinic And Research Institution, Santa Monica, California, United States
🇸🇪
Local Institution, Stockholm, Sweden

and more 1 locations

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)

Phase 3

Completed

Conditions: Chronic Kidney Failure
Kidney Transplantation

Interventions: Drug: Cyclosporine (CsA)
Drug: Belatacept LI (less intensive)
Drug: Belatacept MI (more intensive)

First Posted Date: 2005-11-22

Last Posted Date: 2016-08-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 738

Registration Number: NCT00256750

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
Medical College Of Georgia, Augusta, Georgia, United States

and more 32 locations

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept or Placebo (both as IV & SC solution)
Drug: Abatacept

First Posted Date: 2005-11-16

Last Posted Date: 2014-04-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 87

Registration Number: NCT00254293

Locations: 🇺🇸
Davita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸
The Arthritis Clinic & Carolina Bone & Joint, Charlotte, North Carolina, United States

and more 2 locations

Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study

Phase 2

Completed

Conditions: Deep-Vein Thrombosis

First Posted Date: 2005-11-11

Last Posted Date: 2010-03-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 520

Registration Number: NCT00252005

Locations: 🇸🇪
Local Institution, Vastervik, Sweden

A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control

Phase 3

Completed

Conditions: Diabetes, Type 2

First Posted Date: 2005-11-01

Last Posted Date: 2012-04-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 341

Registration Number: NCT00246987

Locations: 🇦🇺
Tasmania, Melbourne, Victoria, Australia
🇨🇳
Local Institution, Taichung, Taiwan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy